BusinessGalectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsBy Nasdaq OMXJan 25, 2018, 1:31 PM UTC
BusinessGalectin Therapeutics Announces Results from Phase 2b NASH-CX TrialBy Nasdaq OMXDec 5, 2017, 1:15 PM UTC
BusinessGalectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017By Nasdaq OMXDec 4, 2017, 9:00 PM UTC
BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
BusinessGalectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH CirrhosisBy Nasdaq OMXOct 20, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02By Nasdaq OMXSep 12, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceBy Nasdaq OMXSep 5, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 14, 2017, 12:15 PM UTC
